Stonepine Capital Management LLC Makes New Investment in ABIVAX Société Anonyme (NASDAQ:ABVX)

Stonepine Capital Management LLC bought a new position in shares of ABIVAX Société Anonyme (NASDAQ:ABVX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 15,000 shares of the company’s stock, valued at approximately $110,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. ADAR1 Capital Management LLC raised its position in shares of ABIVAX Société Anonyme by 190.1% during the fourth quarter. ADAR1 Capital Management LLC now owns 1,513,393 shares of the company’s stock valued at $11,078,000 after buying an additional 991,781 shares during the last quarter. Franklin Resources Inc. raised its position in shares of ABIVAX Société Anonyme by 10.7% during the fourth quarter. Franklin Resources Inc. now owns 1,466,062 shares of the company’s stock valued at $10,732,000 after buying an additional 141,710 shares during the last quarter. Nantahala Capital Management LLC raised its position in shares of ABIVAX Société Anonyme by 45.7% during the fourth quarter. Nantahala Capital Management LLC now owns 1,436,047 shares of the company’s stock valued at $10,512,000 after buying an additional 450,413 shares during the last quarter. Millennium Management LLC raised its position in shares of ABIVAX Société Anonyme by 44.2% during the fourth quarter. Millennium Management LLC now owns 931,179 shares of the company’s stock valued at $6,816,000 after buying an additional 285,542 shares during the last quarter. Finally, Citadel Advisors LLC raised its position in shares of ABIVAX Société Anonyme by 83.5% during the fourth quarter. Citadel Advisors LLC now owns 855,676 shares of the company’s stock valued at $6,264,000 after buying an additional 389,247 shares during the last quarter. Institutional investors own 47.91% of the company’s stock.

ABIVAX Société Anonyme Price Performance

ABVX stock opened at $6.01 on Friday. The firm has a fifty day moving average price of $6.40 and a 200 day moving average price of $7.25. ABIVAX Société Anonyme has a fifty-two week low of $4.77 and a fifty-two week high of $14.72.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on ABVX. Morgan Stanley reiterated an “equal weight” rating and set a $12.00 price objective on shares of ABIVAX Société Anonyme in a research report on Thursday, March 20th. JMP Securities reiterated a “market outperform” rating and set a $33.00 price objective on shares of ABIVAX Société Anonyme in a research report on Wednesday, April 30th. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, ABIVAX Société Anonyme has an average rating of “Buy” and a consensus target price of $34.00.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.